To assess the level of preparedness of EU/EEA Member States to respond to zoonotic avian flu outbreaks, ECDC has carried out two surveys - one assessing the laboratory capacity for molecular diagnosis and characterisation of zoonotic influenza viruses, and the other focusing on measures applied to protect exposed people during outbreaks of highly pathogenic avian influenza.
The aim of this survey was to review the expertise, capabilities and capacities for detection and characterisation of avian and other zoonotic influenza viruses in national influenza reference laboratories in the European Union/European Economic Area (EU/EEA), in members of the European Reference Laboratories for influenza (ERLINet), and in EU Enlargement policy countries.
This scientific report provides an overview of highly pathogenic avian influenza (HPAI) virus detections in poultry, captive birds, wild birds, and mammals that occurred in and outside Europe between 2 September and 1 December 2023, as well as human cases due to avian influenza viruses up until 1 December 2023.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 26 November - 2 December 2023 and includes updates on human infection with influenza A(H1N2)v, influenza A(H5N1), an overview of respiratory virus epidemiology in the EU/EEA, respiratory infections due to Mycoplasma pneumoniae in the EU/EEA, HIV/AIDS surveillance 2023 (2022 data), West Nile virus, SARS-CoV-2 variant classification, and poliomyelitis.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 19 - 25 November 2023 and includes updates on updates SARS-CoV-2 variant classifications, the increase of pediatric respiratory infections in China, Avian influenza in fur farms, West Nile virus, cholera, and an overview of respiratory virus epidemiology.
A joint study of the National Public Health Organization in Greece (NPHO) and the European Centre for Disease Prevention and Control (ECDC) conducted in 15 Greek hospitals in 2022 sheds light on the rapid spread of carbapenemase-producing, highly drug-resistant Klebsiella pneumoniae sequence type (ST) 39, following its initial documentation in a European-wide genomic survey in 2019.
The main aim of the genomic study described in this surveillance report was to determine the distribution of the highly drug-resistant clade of Klebsiella pneumoniae (sequence type (ST) 39 in Greek hospitals in 2022.